Akebia Therapeutics, Inc. (NASDAQ: AKBA) is a Healthcare company (Biotechnology) with a market capitalization of $111M. The Maz Rating grades it against the other companies in its sector.
Akebia Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.40, Akebia Therapeutics, Inc. trades at 0.6x sales and 5.4x book value. Over the last twelve months it generated about $197M of revenue and a net loss of $44M. It runs a gross margin of 78.9%, an operating margin of -15.7% and a net margin of -22.6%. It shows return on equity of -169.2%, return on invested capital of -14.2% and a free cash flow yield of 12.4%. On the balance sheet: a debt-to-equity ratio of 2.97 and a current ratio of 1.36. Over the past 52 weeks the share price ranged from $0.36 to $1.75, with a beta of 0.23.
Akebia Therapeutics, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 7 Buy, 4 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Akebia Therapeutics, Inc. (AKBA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 23.5% / 30% · (Cash+Inv) / Mkt Cap (36m) 74.4% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 23.5% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 74.4% / 33% · Receivables / Mkt Cap (36m) 17.0% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 23.5% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 74.4% / 33.33% · Receivables / Mkt Cap (24m) 17.0% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 11.2% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 46.3% / 33.33% · Receivables / Avg Assets (4Q) 13.9% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 14.7% / 33.33% · (Cash+ST Inv) / Total Assets 46.5% / 33.33% · (Cash+Recv) / Total Assets 57.2% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Akebia Therapeutics, Inc. (AKBA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Akebia Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
Akebia Therapeutics, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.